Hepatitis D Latest Advances

Analysis of the prevalence status and clinical characteristics of the hepatitis D virus in the Xinjiang region

Journal: Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology

Published: December 10, 2025

WHO URGES ACTION ON HEPATITIS, ANNOUNCING HEPATITIS D AS CARCINOGENIC.

Journal: Neurosciences (Riyadh, Saudi Arabia)

Published: November 25, 2025

Unexpectedly Low Prevalence of Hepatitis Delta Virus Infection in Southern Viet Nam.

Journal: Research square

Published: November 24, 2025

SOLSTICE: tobevibart plus elebsiran for hepatitis D.

Journal: Nature reviews. Gastroenterology & hepatology

Published: November 19, 2025

A Phase 2 Trial of Tobevibart plus Elebsiran in Hepatitis D.

Journal: The New England journal of medicine

Published: November 10, 2025

Prevalence of hepatitis D among patients with hepatitis B: A cross-sectional study.

Journal: Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology

Published: November 05, 2025

The cascade of care for hepatitis B - any lessons from the HIV field?

Journal: Expert review of anti-infective therapy

Published: October 26, 2025

Current evidence of bulevirtide as monotherapy compared to combination treatment with pegylated interferon for hepatitis delta.

Journal: Expert review of anti-infective therapy

Published: October 24, 2025

Ten-Year Follow-Up After 96 Weeks Treatment With Peginterferon Plus Tenofovir in Hepatitis D (HIDIT-II): Improved Clinical Outcome After Combination Therapy.

Journal: United European gastroenterology journal

Published: October 21, 2025

Therapies and Pipeline for Hepatitis B and Hepatitis D.

Journal: Clinics in liver disease

Published: October 18, 2025

WHO urges action on Hepatitis, announcing Hepatitis D as carcinogenic.

Journal: Saudi medical journal

Published: October 14, 2025

Best practices for screening, testing, diagnosing, and treating patients with hepatitis D (delta) virus based on global expert review and recent guidelines.

Journal: Antiviral therapy

Published: September 30, 2025

Filters

Analysis of the prevalence status and clinical characteristics of the hepatitis D virus in the Xinjiang region

Analysis of the prevalence status and clinical characteristics of the hepatitis D virus in the Xinjiang region

WHO URGES ACTION ON HEPATITIS, ANNOUNCING HEPATITIS D AS CARCINOGENIC.

WHO URGES ACTION ON HEPATITIS, ANNOUNCING HEPATITIS D AS CARCINOGENIC.

Unexpectedly Low Prevalence of Hepatitis Delta Virus Infection in Southern Viet Nam.

Unexpectedly Low Prevalence of Hepatitis Delta Virus Infection in Southern Viet Nam.

SOLSTICE: tobevibart plus elebsiran for hepatitis D.

SOLSTICE: tobevibart plus elebsiran for hepatitis D.

A Phase 2 Trial of Tobevibart plus Elebsiran in Hepatitis D.

A Phase 2 Trial of Tobevibart plus Elebsiran in Hepatitis D.

Prevalence of hepatitis D among patients with hepatitis B: A cross-sectional study.

Prevalence of hepatitis D among patients with hepatitis B: A cross-sectional study.

The cascade of care for hepatitis B - any lessons from the HIV field?

The cascade of care for hepatitis B - any lessons from the HIV field?

Current evidence of bulevirtide as monotherapy compared to combination treatment with pegylated interferon for hepatitis delta.

Current evidence of bulevirtide as monotherapy compared to combination treatment with pegylated interferon for hepatitis delta.

Ten-Year Follow-Up After 96 Weeks Treatment With Peginterferon Plus Tenofovir in Hepatitis D (HIDIT-II): Improved Clinical Outcome After Combination Therapy.

Ten-Year Follow-Up After 96 Weeks Treatment With Peginterferon Plus Tenofovir in Hepatitis D (HIDIT-II): Improved Clinical Outcome After Combination Therapy.

Therapies and Pipeline for Hepatitis B and Hepatitis D.

Therapies and Pipeline for Hepatitis B and Hepatitis D.

WHO urges action on Hepatitis, announcing Hepatitis D as carcinogenic.

WHO urges action on Hepatitis, announcing Hepatitis D as carcinogenic.

Best practices for screening, testing, diagnosing, and treating patients with hepatitis D (delta) virus based on global expert review and recent guidelines.

Best practices for screening, testing, diagnosing, and treating patients with hepatitis D (delta) virus based on global expert review and recent guidelines.